Navigation Links
Rhode Island Biotechnology Company Develops Tularemia Vaccine

EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has developed a promising tularemia vaccine // candidate (TuliVaxTM) that confers protective immunity. Francisella tularensis is a bacterium considered to be one of the most dangerous potential bioterror agents.

This vaccine project was funded by a BioDefense Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The animal studies, conducted at Rhode Island Hospital, showed that TuliVaxTM protected mice from lethal bacterial challenge.

“Our unique ability to develop safe and effective vaccines by screening whole genomes for candidate vaccine components with computer algorithms is at the core of this research effort,” said Anne De Groot, M.D., President and CEO of EpiVax. “These study results highlight the ability of our computer-aided vaccine design (VaccineCAD) approach to create effective and innovative vaccines at an accelerated pace”.

Tularemia is rare but does occur naturally; the most lethal pulmonary form is more common in Martha’s Vineyard than in most other places in the world. EpiVax collaborated with Martha’s Vineyard Hospital to obtain bloods from people with previous tularemia infection; 95% of the study participants demonstrated robust responses to the TuliVaxTM components.

Mice with “humanized” immune systems were used by Rhode Island Hospital collaborator Stephen Gregory PhD, Associate Professor of Medicine, Department of Medicine, Rhode Island Hospital and Brown Medical School, to assess the ability of the vaccine to protect against a lethal dose of F. tularensis. Although all of the mice that received a placebo vaccine died when exposed to tularemia, the majority of the mice that received TuliVaxTM survived.

The development of a safe and effective tularemia vaccine has proven elusive; the live vaccine str ain (LVS) of tularensis was the major tularemia vaccine under study for many years. Although it conferred partial protection, federal funding to license LVS has been cancelled due to safety and manufacturing concerns1.

“There is an urgent need for a safe, effective tularemia vaccine to address both natural infections and potential biothreats. TuliVax is likely to be safe because it is composed of small synthetic parts, not the live bacterium”, says Dr. Gregory. “Preliminary results in mice are encouraging; additional experiments are required to provide the data needed for TuliVax to progress to human clinical trials.”



Source-Bio-Bio Technoogy
SRI
'"/>




Related medicine news :

1. Rhode Island legalizes use and possession of Marijuana
2. Meningitis Scare Keeps Children At Home In Rhode Island
3. Rhode Island legalizes use and possession of Marijuana
4. Chikungunya Epidemic On French Island Claims 52 lives
5. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
6. Phoenix Islands To Be Protected Under Global Conservation Map
7. Assams Floating Hospital To Render Medical Services To Islanders
8. Reports Of A HIV Break Out Scare People Of A Holiday Island
9. King Island Water Certified Potable
10. E. coli causes havoc in Fire Island
11. Meningitis Scare Keeps Children At Home In Rhode Island
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology: